Wedbush analyst David Nierengarten added Argenx to the firm’s Best Ideas List and raised his target price for shares to $125 from $121 based on increasing confidence in efgartigimod’s broad market opportunity in antibody-mediated autoimmune diseases. In a research note to investors, Nierengarten says he believes recent share weakness in response to additional disclosed ITP data in the company’s most recent prospectus associated with a share offering is “overblown” and creates an even more attractive entry point for investors. The analyst has an Outperform rating on shares.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.